All systems operational
Q3 2024

Outcomes and Long-Term Survival of Adolescent and Young Adult Patients Admitted to the Intensive Care Unit Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience of 152 Patients

Othman M. Solaiman · Tusneem Elhassan · Riad E. Fakih · Abdul Mannan · Zainab Alduhailib · Ashwaq A. Mahdali · Hazzaa Alzahrani · Mouhamad Jamil · Naeem Chaudhri · Alyaa Elhazmi · Mohammad Kolko · Fahad Z. Al-Sharif · Abdullah Alrbiaan · Mohammed Shaban · Marwan Shaheen · Nawal Salahuddin · Feras A. Alfraih · Ashraf S. Altarifi · Mona Hassanein · Sulaiman Hosaini · Noura Alhashim · Alaa A. Mohamed · Amr Hanbali · Ali H. Aljanoubi · Nadia R. Al-Obaidi · Walid Rasheed · Khalid Maghrabi · Fahad Almohareb · Ayman Soubani · Mahm
10.56875/2589-0646.1114 390 Views 4 Citations
4
Citations
390
Views
Abstract


Background and objectives:
Prognostic factors reliably predicting outcomes for critically ill adolescent and young adult (AYA) patients undergoing allogeneic hematopoietic cell transplantation (allo-HSCT) are lacking. We assessed transplant and intensive care unit (ICU)-related factors impacting patient outcomes.


Patients and methods:
AYA patients who underwent allo-HSCT and required ICU admission at a Tertiary care Centre, during the period of 2003–2013, were included in this retrospective review.
This was a non-interventional study. Only outcomes after the first allo-HSCT and index ICU admissions were analyzed. Disease-, transplant-, and ICU-related variables were analyzed to identify risk factors predictive of survival.


Results:
Overall, 152 patients were included (males, 60.5%); median age at transplantation was 24 years (interquartile range [IQR] 18–32.5); median age at admission to the ICU was 25.8 years (IQR 19–34). Eighty-four percent underwent transplantation for a hematological malignancy; 129 (85%) received myeloablative conditioning. Seventy-one percent of ICU admissions occurred within the first year after allo-HSCT. ICU admission was primarily due to respiratory failure (47.3%) and sepsis (43.4%). One hundred and three patients (68%) died within 28 days of ICU admission. The 1- and 5- year overall survival rates were 19% and 17%, respectively. Main causes for ICU-related death were refractory septic shock with multiorgan failure (n = 49, 32%) and acute respiratory distress syndrome (ARDS) (n = 39, 26%).
Univariate analysis showed that ICU mortality was associated with an Acute Physiology and Chronic Health Evaluation (APACHE) II score >20, a sequential organ failure assessment (SOFA score) > 12, a high lactate level, anemia, thrombocytopenia, leukopenia, hyperbilirubinemia, a high international normalized ratio (INR) and acute graft-versus- host disease (GVHD). Multivariate analysis identified thrombocytopenia, high INR, and acute GVHD as independent predictors of mortality.


Conclusions:
In AYA allo-HSCT patients admitted to the ICU, mortality remains high. Higher SOFA and APACHE scores, the need for organ support, thrombocytopenia, coagulopathy, and acute GVHD predict poor outcomes.

Cite this Article (APA)
Othman, M. S., Tusneem, E., Riad, E. F., Abdul, M., Zainab, A., Ashwaq, A. M., Hazzaa, A., Mouhamad, J., Naeem, C., Alyaa, E., Mohammad, K., Fahad, Z. A., Abdullah, A., Mohammed, S., Marwan, S., Nawal, S., Feras, A. A., Ashraf, S. A., Mona, H., Sulaiman, H., Noura, A., Alaa, A. M., Amr, H., Ali, H. A., Nadia, R. A., Walid, R., Khalid, M., Fahad, A., Ayman, S., Mahm (2024). Outcomes and Long-Term Survival of Adolescent and Young Adult Patients Admitted to the Intensive Care Unit Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience of 152 Patients. Hematology/Oncology and Stem Cell Therapy. https://doi.org/10.56875/2589-0646.1114
Related Papers
The Risk and Prognosis of COVID-19 Infection in Cancer Patients
Ghada M. ElGohary; Shahrukh Hashmi; Jan Styczynski; Mohamed A. Kharfan-Dabaja; R · 2022
80
cites
397
Molecular mediators of breast cancer metastasis
Ragini Yeeravalli; Amitava Das · 2021
39
cites
387
Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia
Nosha Farhadfar; Ying Li; William S. May; Carolyn Brooke Adams · 2021
38
cites
390
Acute upper limb ischemia in a patient with COVID-19
Parminder Kaur; Firas Qaqa; Amr Ramahi; Yezin Shamoon; Monisha Singhal; Fayez Sh · 2021
35
cites
387
Access
View Full Text via DOI
Published in
ISSN 1658-3876
Quartile Q3
AMS Score 72
Field Medicine & Health Sciences
Publisher Elsevier / King Faisal Specialist H
Country 🇸🇦 Saudi Arabia
View Journal Profile →
Authors
Publication Details
Year 2024
Language English
Added 28 Jul 2026